RT Conference Proceedings
T1 Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
A1 Cardoso, F.
A1 Juric, D.
A1 Lerebours, F.
A1 Krop, I.
A1 Borrego, M. Ruiz
A1 Neven, P.
A1 Park, Y. H.
A1 Yardley, D.
A1 Jhaveri, K.
A1 Arce, C.
A1 Gu, E.
A1 Akdere, M.
A1 Rugo, H. S.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/21904
UL http://hdl.handle.net/10668/21904
LA en
DS RISalud
RD Apr 12, 2025